title: Factors influencing influenza-vaccination in adults under immunosuppressive therapy for a systemic inflammatory disease.
abstract: OBJECTIVE
  The aim of this study was to evaluate flu vaccination rates and influencing factors in patients with systemic inflammatory diseases.
  
  
  METHODS
  All patients presenting with a systemic inflammatory disease and taking immunosuppressants, who were hospitalized or had consulted in our internal medicine department between January 2 and 31, 2006, were included in the study. The information concerning flu vaccination was collected with a standardized form.
  
  
  RESULTS
  One hundred and thirty-seven patients (mean age 53.1+/-17.6years; 40 [29%] male patients) were included: 39 (28%) had received flu vaccination in 2005 including 14 (16.7%) of the 84 patients with no other indication for flu vaccination than IS-induced immunodepression and 25 (47.2%) of the 53 patients with other flu vaccination indication(s) (p<0.001). The most frequent reasons for non-vaccination were: absence of physician recommendation (58%), fear of adverse effects (35%) and concern on vaccine clinical effectiveness (5%). The vaccination rate was significantly higher (49%) among patients who remembered having received a voucher from the French National Health Insurance Agency versus 18% among those who did not (OR=4.2 [95%CI, 1.92-9.19] p<0.05). This correlation remained significant after adjustment for confounding factors in a logistic regression model.
  
  
  CONCLUSIONS
  Influenza-vaccination coverage is low in patients receiving immunosuppressive therapy for systemic inflammatory diseases. We have to increase the influenza-vaccination coverage in this population.
authors.affiliation: Pôle de médecine, groupe hospitalier Cochin-Saint-Vincent-de-Paul, AP-HP, université Paris-Descartes, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Lanternier
authors.forename: C
authors.initials: C
authors.lastname: Henegar
authors.forename: L
authors.initials: L
authors.lastname: Mouthon
authors.forename: P
authors.initials: P
authors.lastname: Blanche
authors.forename: B
authors.initials: B
authors.lastname: Christophorov
authors.forename: P
authors.initials: P
authors.lastname: Cohen
authors.forename: B
authors.initials: B
authors.lastname: Bienvenu
authors.forename: V
authors.initials: V
authors.lastname: Le Guern
authors.forename: A
authors.initials: A
authors.lastname: Berezné
authors.forename: C
authors.initials: C
authors.lastname: Pagnoux
authors.forename: L
authors.initials: L
authors.lastname: Guillevin
authors.forename: O
authors.initials: O
authors.lastname: Launay
mesh_terms: D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D007252:Influenza Vaccines; D008297:Male; D008875:Middle Aged; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D007166:Immunosuppressive Agents; D007252:Influenza Vaccines